

Larry's history

I was diagnosed with prostate cancer in the winter of 2022–2023, likely related to Agent Orange exposure in 1974. After a prostatectomy in late 2023, I experienced an immediate recurrence in February 2024 with rapid PSA doubling. Because ADT was unavoidable, I reviewed every option I could find, focusing on side effects that were most important to me, specifically insulin resistance, bone loss, lipid profile, and blood pressure. tE2 appeared to offer fewer side effects with equal efficacy. I began tE2 in April 2024, switched to Orgovyx when tE2 was unavailable, then returned to tE2 and eventually transitioned to estradiol valerate injections. Since October 2024, my PSA has remained undetectable using only E2 and without additional treatment. I have modest breast growth (which is purely cosmetic-no health effects) and have avoided the common health-damaging side effects associated with standard ADTs.